Adjuvant Therapy in Patients with Gallbladder Carcinoma

Şener Cihan, Nebi Serkan Demirci, Hatice Odabas, Nuriye Yıldırım Özdemir, Doğan Yazılıtaş

Şener Cihan, Department of Medical Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey
Nebi Serkan Demirci, Nuriye Yıldırım Özdemir, Doğan Yazılıtaş, Department of Medical Oncology, Ankara Numune Training and Research Hospital, Ankara, Turkey
Hatice Odabas, Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Education and Research Hospital, Istanbul, Turkey
Correspondence to: Şener Cihan, Department of Medical Oncology, Okmeydani Training and Research Hospital, Istanbul, Turkey.
Email: drsenercihan@yahoo.com
Telephone: +90-532-4070379 Fax: +90-212-3145550
Received: November 3, 2014 Revised: December 1, 2014 Accepted: December 6, 2014 Published online: January 21, 2015

ABSTRACT

AIM: This study aimed to investigate the effects of adjuvant therapy and chemotherapeutic agents on survival of patients with gallbladder carcinoma. Factors that may affect survival were examined.

METHOD: The files of 74 patients who had been followed between 2004 and 2013 were retrospectively reviewed. Only stage I-III gallbladder carcinoma patients were included in the study.

RESULTS: The median age was 65 (36-82) years and 55 (74.4%) of the patients were female. Stage I was determined in 12 (16.2%) patients, whereas Stage II and III were determined in 62 (83.8%) patients. All of the patients had undergone surgical intervention. Positive surgical margin was present in 21 (28.4%) patients and 14 (58.4%) of these patients were re-operated. Thirty-nine (52.7%) patients received chemotherapy. The combination of cisplatin-fluorouracil was the most commonly used chemotherapy regimen, received by 15 (38.5%) patients. Radiotherapy alone was performed in none of the patients, while 8 (10.8%) patients received chemoradiotherapy. Whereas DFS was 21±1.7 (17.2-24.9 95% CI) in the adjuvant therapy arm, OS was found to be 24±2.05 (19.9-28.9 95% CI). DFS was 23±6.7 (9.7-36.3 95% CI) and OS was 28±2.8 (22.5-33.5 95% CI) in the patients that did not receive adjuvant therapy. The differences in both DFS ($p=0.246$) and OS were not statistically significant ($p=0.534$). The effectiveness of adjuvant therapy on DFS and OS in the subgroups (surgical margin positivity, stage II patients, older than 65 years old) was statistically significant.

CONCLUSION: There is no standard adjuvant therapy for gallbladder carcinoma. The present study demonstrated the favorable effect of adjuvant therapy, particularly for selected patients. Prospective studies in large patient groups are needed to clarify the benefits of adjuvant therapy.

© 2015 ACT. All rights reserved.

Key words: Carcinoma; Gallbladder; Adjuvant treatment; Survival

Cihan Ş, Demirci NS, Odabas H, Özdemir NY, Yazılıtaş D. Adjuvant Therapy in Patients with Gallbladder Carcinoma. Journal of Gastroenterology and Hepatology Research 2015; 4(1): 1439-1443 Available from: URL: http://www.ghrnet.org/index.php/joghr/article/view/1022

INTRODUCTION

Gallbladder cancer (GBC) is the 5th most common cancer of the gastrointestinal system[1]. It is 2-6 times more prevalent in females[2]. Gallstones (GS) enhance the risk of cancer by leading to chronic inflammation[3] and 80-90% of cancer patients have GS[4,5]. The incidence of cancer in the individuals with GS is 0.5-3%[6]. The disease has quite a poor prognosis. The five-year survival rate is 5-10% and median survival is approximately 3-6 months[6-9]. Surgery is the only curative therapeutic method in early-stage disease. There are studies reporting that the postoperative 5-year survival rate reaches to 90%[10,11]. However, curative surgery is very rare since 80% of GBC are detected at an advanced stage[12,13]. Surgery is usually diagnosed at an advanced stage since there is no specific symptom or sign for GBC, since these symptoms may be seen also in benign diseases such as cholecystitis and cholelithiasis,
and lymphogenous and hematogenous spread is rapid. Surgical excision is the standard method for early-stage disease but there is as yet no consensus on adjuvant therapy. Postoperative radiotherapy and chemotherapy are recommended because of a postoperative local relapse rate of 50%, even after R0 resection. Chemotherapeutics used in adjuvant chemotherapy as single therapy or in combination include 5-Fluorouracil (5-FU), mitomycin, adriamycin, cisplatin and gemcitabine.

**METHODS**

Medical records of patients followed at two different oncology centers were reviewed. Files including the diagnosis of gallbladder cancer made between February 2004 and July 2013 were examined. Cases with bile duct carcinoma, cholangiocellular carcinoma, carcinoma of the ampulla of Vater, and stage IV gallbladder carcinoma were excluded.

Disease free survival (DFS) was determined as the time up to local recurrence, metastasis, death without evidence of disease or last control since surgery. Overall survival (OS) was determined as the time up to death or last control. Both of these were calculated as the mean in months. Statistical analyses were performed with Statistical Package for the Social Sciences (SPSS 20.0) software. Survival analyses were done according to the Kaplan-Meier method, and Fisher’s exact test and chi-square test were used to evaluate nominal variables and numeric data.

**RESULTS**

Clinical and pathological characteristics of patients are summarized in table 1. The median age at diagnosis was 65 (36-82) years and 55 (74.4%) of the patients were female. GS and/or cholecystitis were present in 47 (63.5%) patients. Stage I disease was detected in only 12 (16.2%) patients, while the number of patients with stage II and III disease was 62 (83.8%). A significant relation was determined between poor differentiation and patient age over 65 years (p=0.004), as well as female gender (p=0.007). Stage III disease was more prevalent in female patients (p=0.001), in calculus cholecystitis (p=0.04), and in patients who received chemotherapy (p=0.001).

All of the patients had undergone surgery. Positive surgical margin was detected in 21 (28.4%) patients, of whom only 14 (58.4%) had undergone re-operation. The number of patients who underwent surgery for prediagnosis of cholecystitis with gallstones was 26 (35.2%).

Chemotherapy was used in only 39 (52.7%) patients. None of the patients with stage I disease received chemotherapy. The combination of cisplatin-fluorouracil was the most common chemotherapy regimen, used in 15 (38.5%) patients, the second most common chemotherapy regimen was the combination of mitomycin-5-Fluorouracil, used in 8 (20.5%) patients. 5-FU/calium folinate, gemcitabine/cisplatin, single-agent gemcitabine, and capecitabine/oxaliplatin were the other chemotherapeutic agents used. Chemotherapeutic agents and their doses are summarized in table 2. None of the patients received radiotherapy alone, whereas 6 (8.1%) patients received chemoradiotherapy, all of whom had a positive surgical margin and had not undergone re-operation. Total radiotherapy dose performed varied between 45 and 60 Gy in 25 fractions. In the group receiving adjuvant therapy, DFS was 21±1.7 (17.2-24.9 95% CI) and OS was found to be 24±2.05 (19.9-28.9 95% CI). On the other hand, DFS was 23±6.7 (9.7-36.3 95% CI) and OS was 28±2.8 (22.5-33.5 95% CI) in the group receiving no adjuvant therapy. Adjuvant therapy and survival curves are presented in figure 1 and figure 2. The effectiveness of adjuvant therapy on DFS and OS in the subgroups is summarized in table 3. 5-FU-based chemotherapy regimens had a favorable effect on both DFS (p=0.001) and OS (p=0.001) as compared to the other chemotherapy regimens.

The number of patients who developed progression, and the time to progression in the group receiving adjuvant therapy were 35 (89.7%) and a median of 21 (8-60) months, respectively. Liver was the most common site of metastasis. The number of patients who received chemotherapy in the metastatic phase was 30 (65.2%). Gemcitabine was the most frequently used first-line chemotherapeutic regimen.
performed in 13 (43.3%) patients.

The median follow-up period was 24 (2-70) months. DFS was 22±1.4 (19.4-24.6 95% CI) and OS was 26±1.9 (22.2-29.8 95% CI). DFS rates for 2 and 3 years were 37% and 17%, whereas OS rates were found to be 60% and 30%, respectively. Parameters that might have an effect on DFS and OS are summarized in table 4.

Figure 1

Gallbladder carcinoma is an uncommon but fatal cancer. Although cancer-related symptoms are not cancer-specific, they are similar to the symptoms seen in cholecystitis and cholelithiasis. On radiological examination, neither ultrasound nor tomography findings are specific to the symptoms seen in cholecystitis and cholelithiasis. However, they are not cancer-specific, they are similar to cancer-related symptoms. Therefore, the disease is usually at an advanced stage when diagnosed.

DISCUSSION

Gallbladder carcinoma is an uncommon but fatal cancer. Although cancer-related symptoms are not cancer-specific, they are similar to the symptoms seen in cholecystitis and cholelithiasis. On radiological examination, neither ultrasound nor tomography findings are specific to cancer and may be seen in other inflammatory diseases of the gallbladder. Therefore, the disease is usually at an advanced stage when diagnosed.

Table 3 The efficacy of adjuvant treatment on OS and DFS in selected subgroups.

| Subgroups                  | Adjuvant treatment | No treatment | P value | DFS          | OS          |
|----------------------------|--------------------|--------------|---------|--------------|-------------|
| Surgical margin positivity | Yes                | 17 (23)      | 4 (5.5) | 0.028<0.001  |             |
|                            | No                 | 22 (29.8)    | 31 (41.7) | 0.721 0.045 |             |
| Stage                      | II                 | 19 (25.7)    | 14 (18.9) | 0.046 0.123 |             |
|                            | III                | 24 (32.4)    | 8 (10.8)  | 0.368 0.941 |             |
| Age                        | <=65               | 20 (27)      | 21 (28.4) | 0.001 0.003 | 0.001 0.012 |
|                            | >65                | 19 (25.7)    | 14 (18.9) | 0.001 0.011 |             |
| Cholecystitis              | Yes                | 29 (39.2)    | 18 (24.3) | 0.526 0.932 |             |
|                            | No                 | 10 (13.5)    | 17 (23)   | 0.169 0.301 |             |

OS: overall survival, DFS: disease free survival; *p-value is significant for the no treatment group.

Table 4 Value of Prognostic Factors

| Factor                           | Disease-free survival | Overall survival |
|----------------------------------|-----------------------|------------------|
| Gender                           | 0.902                 | 0.315            |
| Age                              | 0.85                  | 0.929            |
| Cholecystitis with gallstones     | 0.003                 | 0.023            |
| Differentiation                  | 0.05                  | 0.22             |
| LVI                              | 0.048                 | 0.409            |
| Perineural invasion              | 0.043                 | 0.201            |
| Stage                            | 0.001                 | 0.052            |
| Adjuvant therapy                 | 0.246                 | 0.534            |
| Adjuvant chemotherapy            | 0.323                 | 0.106            |
| Adjuvant chemoradiotherapy        | 0.672                 | 0.122            |
| LVI: lymphovascular invasion     |                       |                  |

Surgery is a therapeutic option with a chance of cure in early-stage patients. There is no consensus on the surgical method necessary to be performed. Cholecystectomy is deemed adequate for Tis and T1a tumors. Radical cholecystectomy (cholecystectomy, liver resection and lymph node dissection) is recommended for advanced-stage tumors. However, relapses are quite prevalent in patients particularly with T3 and lymph node involvement even after R0 resection, in which the tumor is removed as a whole. There are studies that report postoperative 5-year survival rates to be low as 5-11.8%, as well as studies that report 5-year survival rate to be 50.7%. In the present study, 3-year DFS and OS rates in the patients that had undergone surgery alone without adjuvant therapy were 33% and 25.3%, respectively. Todoroki et al defended the viewpoint that radical cholecystectomy can be performed even in stage IV disease.

Poor prognosis after surgery alone has brought forward chemotherapy and/or radiotherapy as adjuvant settings. Today, there is as yet no standard practice for adjuvant therapy. Jarnagin et al conducted a study in 97 patients that had undergone radical cholecystectomy and found the incidence of distant metastasis to be 85% and local relapse to be 15%.[16] Incidence of distant metastasis has brought adjuvant chemotherapy as a systemic treatment. The most comprehensive randomized study for adjuvant chemotherapy was done by Takada et al[17]. This study comprised other cancers of the pancreaticobiliary system. In this study, in which the number of cases with gallbladder cancer was 118 and a combination of mitomycin C/fluorouracil was used as the adjuvant chemotherapy, the 5-year survival rate was 26% in the group receiving chemotherapy and 14.4% in the group that underwent surgery alone. These results are statistically significant as well (p=0.036). In subgroup analyses, it was reported that chemotherapy was beneficial also in the group that did not undergo surgery.
not undergo curative surgery.

Adjuvant chemoradiotherapy has become a current issue for preventing local relapses, particularly in cases that have a positive surgical margin. Information on the efficacy of radiotherapy has been obtained from retrospective studies. Although there are studies that demonstrate survival benefits of radiotherapy alone or in combination with adjuvant therapies, particularly when used at a dose >40Gy with fluoropyrimidine,[25-27] there are also studies demonstrating that it does not provide a survival advantage.[30] Wang et al investigated the efficacy of adjuvant radiotherapy alone and chemoradiotherapy in two different studies and similarly reported that >T2 node-positive patients benefited from adjuvant therapies.[31,32]

Horgan et al carried out a meta-analysis and compared the group that underwent surgery alone with the group receiving any adjuvant therapy after surgery, but failed to find a significant difference in terms of survival.[33] However, subgroup analyses revealed that node-positive and surgical margin-positive cases benefited from adjuvant therapy. Nevertheless, this analysis also failed to make a clear definition as to which therapeutic modality (chemotherapy or chemoradiotherapy) is the most effective in high-risk patients and whether adjuvant therapy is necessary in low-risk patients.

The efficacy of neoadjuvant therapies on locally advanced disease that cannot be resected has been investigated, but none of these studies reported a statistically significant survival advantage.[34-36]

There is no standard adjuvant therapy because of the limited number of studies defining the role of adjuvant therapy in gallbladder carcinomas. Despite inadequate evidence, adjuvant therapy is recommended in patients with ≥T2, positive surgical margin and positive node since these are strong prognostic factors.[37]

In the present study, none of the treatment modalities had a significant benefit on survival. This unfavorable effect can be explained by poorer risk factors in the patients that received adjuvant therapy. However, longer DFS and OS were obtained in the group receiving adjuvant treatment. Comparing 5-FU-based chemotherapeutic regimens with other agents, its favorable effect on both DFS (p=0.001) and OS (p=0.001) is also consistent with the literature.

The fact that the majority of the studies in the literature comprise hepatobiliary cancers whereas the present study comprises only gallbladder cancers makes this unfavorable effect notable. Prospective randomized studies are required to eliminate conflicting results on adjuvant therapy for gallbladder cancers.

CONFLICT OF INTERESTS

There are no conflicts of interest with regard to the present study.

REFERENCES

1 Gourgiotis S, Kocher HM, Solaini I, Yarollahi A, Tsiambas E, Salemis NS. Gallbladder cancer. *Am J Surg* 2008; **196**: 252-264
2 Zhu AX, Hong TS, Hezel AF, Kooby DA. Current management of gallbladder carcinoma. *Oncologist* 2010; **15**: 168-181
3 Hueman MT, Vollmer CM Jr, Pawlik TM. Evolving treatment strategies for gallbladder cancer. *Surg Oncol Ann* 2009; **16**: 2101-2115
4 Bosset JF, Mantion G, Gillet M, Pelissier E, Boulenger M, Main- gon P, Corbon O, Schraub S. Primary carcinoma of the gallbladder. Adjuvant postoperative external irradiation. *Cancer* 1989; **64**: 1843-187
5 Houry S, Barrier A, Huguier M. Irradiation therapy for gallbladder carcinoma: recent advances. *J Hepatobiliary Pancreat Surg* 2001; **8**: 518-524
6 Piehler JM, Crichlow RW. Primary carcinoma of the gallbladder. *Surg Gynecol Obstet* 1978; **147**: 929-942
7 Bartlett DL, Fong Y, Fortner JG, Brennan MF, Blumgart LH. Long-term results after resection for gallbladder cancer. Implications for staging and management. *Ann Surg* 1996; **224**: 639-646
8 Cubertafond P, Gainant A, Cucchiaro G. Surgical treatment of 724 carcinomas of the gallbladder. Results of the French Surgical Association Survey. *Ann Surg*, 1994; **219**: 275-280
9 Lazcano-Ponce EC, Miquel JP, Munoz N. Epidemiology and molecular pathology of gallbladder cancer. *CA Cancer J Clin* 2002; **51**: 349-364
10 Henson DE, Albores-Saavedra J, Corle D. Carcinoma of the gall- bladder. Histologic types, stage of disease, grade, and survival rates. *Cancer* 1992; **70**: 1493-1497
11 Chijiiwa K, Tanaka M. Carcinoma of the gallbladder: an appraisal of surgical resection. *Surgery* 1994; **115**: 751-756
12 Ogura Y, Mizumoto R, Isaji S, Kusuda T, Matsuda S, Tabata M. Radical operations for carcinoma of the gallbladder: present status in Japan. *World J Surg* 1991; **15**: 337-343
13 Schauer RJ, Meyer G, Baretton G, Schildberg FW, Rau HG. Prognostic factors and long-term results after surgery for gallbladder carcinoma: a retrospective study of 127 patients. *Langenbecks Arch Surg* 2001; **386**: 110-117
14 Jarnagin WR, Ruo L, Little SA, Klimstra D, D’Angelica M, De-Matteo RP, Waganman R, Blumgart LH, Fong Y. Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies. *Cancer* 2003; **98**: 1689-1700
15 Murakami Y, Uemura K, Sudo T, Hayashidani Y, Hashimoto Y, Nakamura H, Nakashima A, Sueda T. Gemcitabine-based adjuvant chemotherapy improves survival after aggressive surgery for hilar cholangiocarcinoma. *J Gastrointest Surg* 2009; **13**: 1470-1479
16 Takada T, Amano H, Yasuda H, Nimura Y, Matushii T, Kato H, Nagakawa T, Nakayama T. Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Is postoperative adjuvant chemotherapy useful for gallbladder carci- noma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreatic biliary carcinoma. *Cancer* 2002; **95**: 1685-1695
17 Eckel F, Brunner T, Jelic S. ESMO Guidelines Working Group. Biliary cancer: ESMO clinical recommendation for diagnosis, treatment and follow-up. *Ann Oncol* 2011; **22**: 42-44
18 Medonald OK, Crane CH. Palliative and postoperative radiotherapy in biliary tract cancer. *Surg Oncol Clin N Am* 2002; **11**: 941-954
19 Czito BG, Hurwitz HL, Clough RW, Tyler DS, Morse MA, Clary BM, Pappas TN, Fernando NH, Willett CG. Adjuvant external-beam radiotherapy with concurrent chemotherapy after resection of primary gallbladder carcinoma: a 23-year experience. *Int J Radiat Oncol Biol Phys* 2005; **62**: 1030-1034
20 Kresl JJ, Schild SE, Henning GT, Gunderson LL, Donohue J, Pitot H, Haddock MG, Nagorney D. Adjuvant external beam radiation therapy with concurrent chemotherapy in the management of gall- bladder carcinoma. *Int J Radiat Oncol Biol Phys* 2002; **52**: 167-175
21 Todoroki T. Chemotherapy for bile duct carcinoma in the light of adjuvant chemotherapy to surgery. *Hepatogastroenterology* 2000; **47**: 644-649
22 Onoyma H, Yamamoto M, Takada M, Urakawa T, Ajiki T, Yamada I, Fujita T, Saitoh Y. Diagnostic imaging of early gallbladder cancer: retrospective study of 53 cases. *World J Surg* 1999; **23**: 708-712
23 Otkarinen H, Paivansalo M, Lahde S, Tikkakoski T, Saramo I. Radiological findings in cases of gallbladder carcinoma. *Eur J Radiol* 1993; **17**: 179-183

© 2015 ACT. All rights reserved.
Archer A, Horton K. Radiologic evaluation and treatment of gallbladder and biliary tree carcinoma. *Cancer Treat Res* 1994; 69: 157-183

Foster JM, Hoshi H, Gibbs JE, Iyer R, Javle M, Chu Q, Kuvshinoff B. Gallbladder cancer: defining the indications for primary radical resection and radical re-resection. *Ann Surg Oncol* 2007; 14: 833-840

Muratore A, Polastri R, Bouzari H. Radical surgery for gallbladder cancer: a worthwhile operation? *Eur J Surg Oncol* 2000; 26: 160-163

Donohue JH, Nagorney DM, Grant CS, Tsushima K, Istrup DM, Adson MA. Carcinoma of the gallbladder. Does radical resection improve outcome? *Arch Surg* 1990; 125: 237-241

Todoroki T, Kawamoto T, Takahashi H. Treatment of gallbladder cancer by radical resection. *Br J Surg* 1999; 86: 622-627

Mojica P, Smith D, Ellenhorn J. Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease. *J Surg Oncol* 2007; 96: 8-13

Gold DG, Miller RC, Haddock MG, Gunderson LL, Quevedo F, Donohue JH, Bhatia S, Nagorney DM. Adjuvant therapy for gallbladder carcinoma: the Mayo Clinic Experience. *Int J Radiat Oncol Biol Phys* 2009; 75: 150-155

Mahe M, Stampfl C, Romestaing P, Salerno N, Gerard JP. Primary carcinoma of the gall-bladder: potential for external radiation therapy. *Radiother Oncol* 1994; 33: 204-208

Mehta A, Bahadur AK, Aranya RC, Jain AK. Role of radiation therapy in carcinoma of the gallbladder: a preliminary indian experience. *Trop Gastroenterol* 1996; 17: 22-25

Chao TC, Jan YY, Chen MF. Primary carcinoma of the gallbladder associated with anomalous pancreaticobiliary ductal junction. *J Clin Gastroenterol* 1995; 21: 306-308

Wang SJ, Fuller CD, Kim JS, Stittig DF, Thomas CR Jr, Ravdin PM. Prediction model for estimating the survival benefit of adjuvant radiotherapy for gallbladder cancer. *J Clin Oncol* 2008; 26: 2112-2117

Wang SJ, Lemieux A, Kalpathy-Cramer J, Ord CB, Walker GV, Fuller CD, Kim JS, Thomas CR Jr. Nomogram for predicting the benefit of adjuvant chemoradiotherapy for resected gallbladder cancer. *J Clin Oncol* 2011; 29: 4627-4632

Horgan AM, Amir E, Walter T, Knox JJ. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis. *J Clin Oncol* 2012; 30: 1934-1940

Kaneoka Y, Yamaguchi A, Isogai M, Harada T, Suzuki M. Hepatoduodenal ligament invasion by gallbladder carcinoma: histologic patterns and surgical recommendation. *World J Surg* 2003; 27: 260-265

Lin LL, Picus J, Drehin JA, Linehan DC, Solis J, Strasberg SM, Tan B, Thorstad WL, Myerson R. A phase II study of alternating cycles of split course radiation therapy and gemcitabine chemotherapy for inoperable pancreatic or biliary tract carcinoma. *Am J Clin Oncol* 2005; 28: 234-241

Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, Lawrence TS, McGinn CJ. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. *J Gastrointest Surg* 2003; 7: 766-7672

Ben-David MA, Griffith KA, Abu-Isa E, Lawrence TS, Knol J, Zalupski M, Ben-Josef E. External-beam radiotherapy for localized extrahepatic cholangiocarcinoma. *Int J Radiat Oncol Biol Phys* 2006; 66: 772-779

Peer reviewer: Yoshiaki Kawaguchi, Associate Professor, Department of Gastroenterology, Tokai University School of Medicine, 143 Shomokasuya, Isehara, 259-1193, Japan.